First and Only CD19-Targeted Therapy Approved in Europe for Adults with anti-AChR+ and anti-MuSK+ gMGUPLIZNA Demonstrates Durable Disease Control with Twice-Yearly Dosing*THOUSAND OAKS, Calif.
Unele rezultate au fost ascunse, deoarece pot fi inaccesibile pentru dvs.
Afișați rezultatele inaccesibile